SCHEMBL22700375

SCHEMBL22700375

CC1=C(C2=C(C)C(=O)c3c(c(/C=N/NC(=O)c4ccncc4)c(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.41
MEN1 O00255 9/20 0.41
KMT2A Q03164 9/20 0.41
MAPT P10636 7/20 0.41
ALDH1A1 P00352 5/20 0.41
GAA P10253 2/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 4/20 0.41
MAPK1 P28482 1/20 0.41
RECQL P46063 1/20 0.41
NPC1 O15118 5/20 0.40
L3MBTL1 Q9Y468 5/20 0.40
USP2 O75604 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PAX8 Q06710 1/20 0.39
HPGD P15428 1/20 0.39
MPO P05164 2/20 0.39
NT5E P21589 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22700765 0.84 SMN1; SMN2 (0.32) KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL22700720 0.80 MAPT (0.42) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22700398 0.78 MEN1 (0.35) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22700400 0.77 MAPT (0.36) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22700390 0.77 MCL1 (0.50) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22686504 0.76 ALB (0.42) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22700704 0.75 MCL1 (0.46) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22700775 0.74 MAOA (0.36) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL22700489 0.74 BCL2 (0.40) MEN1KMT2A
SCHEMBL22700415 0.74 AKR1B1 (0.35) KDM4EMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369618-A1 ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF Nearmedic International Limited (CY) 2020-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369618-A1 ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF DNM2, DNM1, MAVS KDM4E 2116/4885MEN1 3688/4885KMT2A 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.